Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"

NCT00927732 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT00927732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"
Lead sponsor
Nantes University Hospital
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2009
Completion date
October 31, 2014
Enrollment
64 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

brugada syndrome